Marketed in the past by AstraZeneca as Pulmicort, budesonide is an off-patent inhaled steroid and could be used to prevent the risk of people getting seriously ill with the disease, if taken ...
Objective: To review the basis for the estimated comparative daily dosages of inhaled corticosteroids for children and adults that are presented in the National Heart, Lung, and Blood Institute's ...
AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...
Airsupra (albuterol/budesonide) is a brand-name inhaler prescribed for asthma in adults. As with other drugs, Airsupra can cause side effects, such as headache and cough. Airsupra can cause ...
Breztri will be the first inhaler in AstraZeneca’s portfolio ... It is a fixed-dose combination of a corticosteroid (budesonide), a long-acting muscarinic antagonist (glycopyrronium) and a ...
Philip Morris International PM-0.67%decrease; red down pointing triangle expects to take a $220 million loss on the sale of its inhaled-therapeutics unit to Molex Asia Holdings as it retools its ...